Compare PRAX & CPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | CPA |
|---|---|---|
| Founded | 2015 | 1947 |
| Country | United States | Panama |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.9B |
| IPO Year | 2020 | 2005 |
| Metric | PRAX | CPA |
|---|---|---|
| Price | $305.51 | $146.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | ★ $572.13 | $159.40 |
| AVG Volume (30 Days) | ★ 329.6K | 270.2K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 6.09% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $15.51 |
| Revenue Next Year | $7,758.26 | $7.25 |
| P/E Ratio | ★ N/A | $9.05 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.25 | $107.44 |
| 52 Week High | $366.52 | $160.47 |
| Indicator | PRAX | CPA |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 53.32 |
| Support Level | $284.87 | $142.23 |
| Resistance Level | $331.21 | $147.73 |
| Average True Range (ATR) | 16.88 | 3.77 |
| MACD | -2.16 | -0.02 |
| Stochastic Oscillator | 34.34 | 69.69 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Copa Holdings SA is a provider of airline passenger and cargo services through its subsidiaries. The company operates through the air transportation segment. It offers international air transportation for passengers, cargo, and mail, operating from its Panama City hub in the Republic of Panama, and domestic and international air transportation for passengers, cargo, and mail with a point-to-point route network through Copa Colombia, a Colombian air carrier. The company's geographical segments are North America, South America, Central America, and the Caribbean. It derives the maximum revenue from North America.